Loading stock data…
$2.41-0.12 (-4.74%)
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
Seres Therapeutics, Inc. in the Healthcare sector is trading at $2.41 with a market capitalization of $46M. Wall Street consensus targets $17.00 (2 analysts), implying a +605.4% move over the next 12 months. The stock is currently near its 52-week low of $2.38, remaining 69.5% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $736,000↑ | $358,000↓ | $789,000 | $0 | $0 |
| Gross Profit | $736,000↑ | $358,000↑ | $197,000↑ | -$736,000↑ | -$1.69M |
| Operating Income | -$15.47M↑ | -$20.91M↓ | -$19.38M↑ | -$22.48M↑ | -$24.88M |
| Net Income | $4.58M↑ | -$19.91M↓ | -$15.34M↓ | $8.20M↑ | -$19.86M |
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integr...